Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
OMECLAMOX-PAK is a fixed-dose combination oral antibiotic therapy containing amoxicillin, clarithromycin, and omeprazole. It is designed to treat Helicobacter pylori infection and associated peptic ulcer disease by combining two antibiotics with a proton pump inhibitor. This triple-therapy regimen works by reducing gastric acid while simultaneously attacking the bacterial pathogen.
Product faces moderate competitive pressure (score: 30/100) with declining market exclusivity; expect smaller commercial teams focused on retention rather than expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on OMECLAMOX-PAK offers limited career growth potential given its LOE-approaching status and zero current job openings. This role would suit professionals focused on market defense, managed care negotiations, and mature portfolio management rather than growth-oriented career trajectories.
Worked on OMECLAMOX-PAK at Cumberland Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.